Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
- ZORYVE foam was approved by the FDA for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023.
- 80% of individuals achieved the primary efficacy endpoint of Investigator Global Assessment (IGA) Success, and 51% reached complete clearance at Week 8.
- ZORYVE foam demonstrated a statistically significant improvement compared to vehicle on IGA Success at Week 2, the first timepoint assessed in STRATUM.
- More than 60% of individuals achieved a ≥4-point reduction in itch at Week 8.
- ZORYVE foam was well-tolerated with a favorable safety and tolerability profile.
- The most common adverse reactions reported include nasopharyngitis, nausea, and headache, with low incidence and mild to moderate severity.
- None.
Insights
The approval of ZORYVE® for seborrheic dermatitis represents a significant advancement in dermatological treatments, particularly given the lack of innovation in this area over the past two decades. The data from the STRATUM trial demonstrates a high efficacy rate with 80% of patients achieving the primary efficacy endpoint. This is noteworthy as it suggests a strong potential for market penetration, given that the treatment is both steroid-free and effective for a wide demographic (individuals 9 years and older).
From a medical research perspective, the early and significant improvement in symptoms, such as itch and erythema, is a compelling aspect of ZORYVE®'s profile. The reduction in itch by 28% within 48 hours could translate into a strong patient preference for this treatment. Additionally, the favorable safety profile with no serious adverse events reported further supports its potential as a first-line therapy. The impact on patient quality of life, as indicated by the improvements in Dermatology Life Quality Index, could be a driving factor for both patient and clinician adoption of the treatment.
From a market perspective, the approval of ZORYVE® foam is likely to disrupt the current seborrheic dermatitis treatment landscape. As the first treatment with a novel mechanism of action approved in over two decades, Arcutis Biotherapeutics is positioned to capture a significant share of the market. The high efficacy and steroid-free formulation address unmet needs in the patient population, which could result in rapid adoption and increased sales. Market analysts will monitor the uptake of ZORYVE® closely, as it could set a new standard in the treatment of seborrheic dermatitis.
Investors should consider the broader implications of this approval, such as potential expansions into international markets or the development of additional formulations. The positive data from the STRATUM trial could also spur investor confidence in Arcutis Biotherapeutics' pipeline and its ability to innovate in the immuno-dermatology space.
Financially, the approval of ZORYVE® foam by the FDA has the potential to be a strong growth driver for Arcutis Biotherapeutics. The company's stock performance is likely to reflect the commercial success of the product, which is dependent on factors such as market adoption rates, pricing strategies and insurance coverage. Investors will also be attentive to the company's marketing and sales strategies to gauge the potential for return on investment.
Given the treatment's demonstrated efficacy and safety, it may command premium pricing, especially in the absence of direct competitors. However, the company will need to balance pricing with accessibility to maximize market penetration. Long-term financial success will depend on sustained clinical outcomes, maintaining a favorable safety profile and the ability to fend off competition from other pharmaceutical companies that may develop alternative treatments.
- Novel steroid-free topical foam effectively controls seborrheic dermatitis
- Once-daily ZORYVE® (roflumilast) topical foam,
0.3% , is approved to treat seborrheic dermatitis in individuals 9 years of age and older
WESTLAKE VILLAGE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of American Academy of Dermatology (JAAD) published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam,
“Despite being very common, seborrheic dermatitis has traditionally been a disease with limited treatment options. It also can have a significant impact on quality of life,” stated Dr. Andrew Blauvelt, MD, MBA, lead study author and investigator at the Oregon Medical Research Center. “The publication of the Phase 3 STRATUM study results in the Journal of American Academy of Dermatology further validates the significance of roflumilast foam as a new treatment option for seb derm, one that provides treatment success in eight of ten patients, along with significant and rapid improvements in key signs and symptoms of disease, as early as two weeks. These results highlight the effectiveness and safety of roflumilast foam, a steroid-free treatment and the first novel mechanism of action approved for seb derm in two decades. It should end suffering from this long-neglected condition.”
“Seborrheic dermatitis is challenging to manage, and often people with the disease require several different treatments for different areas of their body. Our focus has been to simplify the treatment of seborrheic dermatitis with an effective once-daily steroid-free foam that is suitable for use anywhere on the body for any duration and on all hair and skin types,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis. “We are pleased that this manuscript is now available to provide dermatology clinicians with a greater understanding of the clinical data supporting ZORYVE foam as a newly approved treatment option for their patients.”
The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of ZORYVE (roflumilast) foam,
- The STRATUM study met its primary endpoint, with
80% of roflumilast foam treated individuals reaching IGA Success rate at Week 8 (79.5% ZORYVE foam vs.58.0% vehicle; p<0.0001). IGA Success was defined as an IGA score of clear or almost clear plus a ≥2 grade improvement from baseline. - Improvement was seen early, with roflumilast foam demonstrating a statistically significant improvement compared to vehicle on IGA Success at Week 2, the first timepoint assessed in STRATUM.
- In addition,
50.6% of individuals in the roflumilast foam treated arm reached complete clearance (IGA=0) at Week 8. - Roflumilast foam also demonstrated statistically significant improvement over vehicle on all secondary endpoints, including itch, scaling, and erythema (redness).
- More than
60% of individuals achieved a ≥4-point reduction in itch at Week 8 as measured by Worst Itch-Numerical Rating Score (62.8% roflumilast foam vs.40.6% vehicle; p=0.0001), and significant improvements in itch were also reported at Week 2 and Week 4. - Individuals treated with ZORYVE foam reported a
28% improvement in itch from baseline in 48 hours (compared to13% on vehicle nominal p=0.0024). - More than
50% of individuals treated with ZORYVE foam achieved an erythema (redness) score of 0, and more than50% achieved a scaling score of 0, at Week 8.
- More than
- Treatment with ZORYVE foam demonstrated a significantly larger improvement in patient reported outcomes as early as Week 2 as measured through Dermatology Life Quality Index (DLQI), with improvements maintained through Week 8.
ZORYVE foam was well-tolerated with a favorable safety and tolerability profile. The incidence of Treatment Emergent Adverse Events (TEAEs) was low and similar between active treatment and vehicle, with most TEAEs assessed as mild to moderate severity. There were no treatment-related Serious Adverse Events (SAEs). The most common adverse reactions (≥
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two U.S. FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.
INDICATION
ZORYVE foam,
IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥
Please see full Prescribing Information.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential of ZORYVE foam to simplify disease management for care of seborrheic dermatitis; the potential of real-world use results of ZORYVE foam, as well as the commercial launch of ZORYVE foam in seborrheic dermatitis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 28, 2023, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
asheldon@arcutis.com
Investors
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
What is the FDA approval status of ZORYVE foam? What is the age group for which it is approved?
What were the primary efficacy results from the STRATUM trial?
How did ZORYVE foam perform compared to the vehicle at Week 2 of the STRATUM trial?
What percentage of individuals achieved a significant reduction in itch at Week 8?
What is the safety and tolerability profile of ZORYVE foam?
